Text version
Your next patient is a 20-year-old young man hospitalized with a third episode of psychosis. His first episode was about a year ago, and the second shortly after that. There is no apparent affective component, family history thereof, or substance use. The patient’s working diagnosis is schizophrenia, and you were considering olanzapine, risperidone, and aripiprazole, as you would like to open the possibility of an injectable long-acting antipsychotic at the end of this hospitalization. Would it make any difference to you if you knew that he was at high risk for metabolic syndrome? The authors of our article from Lancet Psychiatry know that you’re in a tough spot. In their discussion, Benjamin Perry and colleagues conclude, “Antipsychotic selection must strike an intricate balance between caring for psychiatric and physical health.”
Hi! Jim Phelps here for the Psychopharmacology Institute. Let’s look at the idea of a psychosis-metabolic risk calculator as presented
Unlock this Quick Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.
Already have an account? Sign in
